Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK/ROS1+ GI Malignancies
NCT02638909Phase 2Terminated
- Sponsor
- Criterium
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ceritinib in colorectal adenocarcinoma, cholangiocarcinoma (CCA), pancreatic adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), gastric adenocarcinoma, sponsored by Criterium. Started Dec 2015; status: terminated.
02
Drugs
ceritinib
03
Conditions
colorectal adenocarcinomacholangiocarcinoma (CCA)pancreatic adenocarcinoma (PDAC)hepatocellular carcinoma (HCC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02638909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638909.